AU2016286108B2 - BTLA fusion protein agonists and uses thereof - Google Patents

BTLA fusion protein agonists and uses thereof Download PDF

Info

Publication number
AU2016286108B2
AU2016286108B2 AU2016286108A AU2016286108A AU2016286108B2 AU 2016286108 B2 AU2016286108 B2 AU 2016286108B2 AU 2016286108 A AU2016286108 A AU 2016286108A AU 2016286108 A AU2016286108 A AU 2016286108A AU 2016286108 B2 AU2016286108 B2 AU 2016286108B2
Authority
AU
Australia
Prior art keywords
hvem
protein
btla
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016286108A
Other languages
English (en)
Other versions
AU2016286108A1 (en
AU2016286108A8 (en
Inventor
Tigran Aivazian
Natasha K. Crellin
Brian Miller
John Sedy
Carl F. Ware
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL, Sanford Burnham Prebys Medical Discovery Institute filed Critical Pfizer Corp Belgium
Publication of AU2016286108A1 publication Critical patent/AU2016286108A1/en
Publication of AU2016286108A8 publication Critical patent/AU2016286108A8/en
Application granted granted Critical
Publication of AU2016286108B2 publication Critical patent/AU2016286108B2/en
Priority to AU2021203768A priority Critical patent/AU2021203768B2/en
Priority to AU2023202302A priority patent/AU2023202302A1/en
Assigned to PFIZER INC., Sanford Burnham Prebys Medical Discovery Institute reassignment PFIZER INC. Request to Amend Deed and Register Assignors: PFIZER INC., SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2016286108A 2015-06-30 2016-06-29 BTLA fusion protein agonists and uses thereof Active AU2016286108B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021203768A AU2021203768B2 (en) 2015-06-30 2021-06-08 BTLA fusion protein agonists and uses thereof
AU2023202302A AU2023202302A1 (en) 2015-06-30 2023-04-14 BTLA fusion protein agonists and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187105P 2015-06-30 2015-06-30
US62/187,105 2015-06-30
PCT/US2016/040108 WO2017004213A1 (en) 2015-06-30 2016-06-29 Btla fusion protein agonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203768A Division AU2021203768B2 (en) 2015-06-30 2021-06-08 BTLA fusion protein agonists and uses thereof

Publications (3)

Publication Number Publication Date
AU2016286108A1 AU2016286108A1 (en) 2018-02-15
AU2016286108A8 AU2016286108A8 (en) 2018-02-22
AU2016286108B2 true AU2016286108B2 (en) 2021-03-11

Family

ID=57609132

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016286108A Active AU2016286108B2 (en) 2015-06-30 2016-06-29 BTLA fusion protein agonists and uses thereof
AU2021203768A Active AU2021203768B2 (en) 2015-06-30 2021-06-08 BTLA fusion protein agonists and uses thereof
AU2023202302A Abandoned AU2023202302A1 (en) 2015-06-30 2023-04-14 BTLA fusion protein agonists and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021203768A Active AU2021203768B2 (en) 2015-06-30 2021-06-08 BTLA fusion protein agonists and uses thereof
AU2023202302A Abandoned AU2023202302A1 (en) 2015-06-30 2023-04-14 BTLA fusion protein agonists and uses thereof

Country Status (13)

Country Link
US (3) US10961297B2 (cg-RX-API-DMAC7.html)
EP (1) EP3317297A4 (cg-RX-API-DMAC7.html)
JP (4) JP7116285B2 (cg-RX-API-DMAC7.html)
KR (2) KR102669985B1 (cg-RX-API-DMAC7.html)
CN (2) CN114853903A (cg-RX-API-DMAC7.html)
AU (3) AU2016286108B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017028316A2 (cg-RX-API-DMAC7.html)
CA (1) CA2990885A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890171A1 (cg-RX-API-DMAC7.html)
IL (2) IL256383B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018000073A (cg-RX-API-DMAC7.html)
SG (1) SG10201913567QA (cg-RX-API-DMAC7.html)
WO (1) WO2017004213A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
BR112017028316A2 (en) 2015-06-30 2018-09-04 Sanford-Burnham Medical Research Institute btla fusion protein agonists and uses thereof
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063067A2 (en) * 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
WO2013074738A1 (en) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
AU2003243781A1 (en) 2002-06-24 2004-01-06 Amniotech, Inc. Amniotic membrane mediated delivery of bioactive molecules
WO2004039394A1 (en) 2002-10-25 2004-05-13 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2004325035B2 (en) * 2004-11-12 2011-09-08 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2010006071A1 (en) 2008-07-08 2010-01-14 La Jolla Institute For Allergy And Immunology Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use
US8349320B2 (en) * 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
JPWO2007010692A1 (ja) 2005-07-19 2009-01-29 独立行政法人科学技術振興機構 Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法
NZ577085A (en) 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
US8318662B2 (en) 2009-03-16 2012-11-27 Korea Institute Of Radiological & Medical Sciences Protein increasing cell infectivity of herpes simplex virus and use thereof
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
MX2012001417A (es) 2009-07-31 2012-07-03 Organon Nv Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla).
US10759863B2 (en) 2013-09-05 2020-09-01 Sanford Burnham Prebys Medical Discovery Institute Modulation of γδ T cells
JP6890546B2 (ja) 2015-04-02 2021-06-18 メモリアル スローン ケタリング キャンサー センター Ｔｎｆｒｓｆ１４／ｈｖｅｍタンパク質およびその使用の方法
JP2018521959A (ja) 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
BR112017028316A2 (en) 2015-06-30 2018-09-04 Sanford-Burnham Medical Research Institute btla fusion protein agonists and uses thereof
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
JP2019528082A (ja) 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
US12281339B2 (en) 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
BR112019020940A2 (pt) 2017-04-11 2020-05-05 Inhibrx, Inc. construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas
EP3630148A4 (en) 2017-05-26 2021-06-16 The Johns Hopkins University MULTIFUNCTIONAL ANTIBODY LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE
JP2021500394A (ja) 2017-10-27 2021-01-07 シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法
WO2019094559A2 (en) 2017-11-09 2019-05-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
PE20210342A1 (es) 2018-05-25 2021-02-23 Alector Llc Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
CN112533629A (zh) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
CN112384532B (zh) 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
WO2020041361A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
CA3109563A1 (en) 2018-09-14 2020-03-19 Universite De Lausanne Methods for modulating regulatory t cells and inhibiting tumor growth
EP3880711A4 (en) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063067A2 (en) * 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
WO2013074738A1 (en) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEUNG TIMOTHY C ET AL, Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway., PROC. NATL. ACAD. SCI. USA (2005), VOL. 102, NR. 37, PAGES 13218 - 13223 *
J. R. SEDY ET AL, "CD160 Activation by Herpesvirus Entry Mediator Augments Inflammatory Cytokine Production and Cytolytic Function by NK Cells", THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 2, pages 828 - 836 *

Also Published As

Publication number Publication date
EA201890171A1 (ru) 2018-08-31
CN108026159A (zh) 2018-05-11
IL297395A (en) 2022-12-01
AU2023202302A1 (en) 2023-05-11
KR102669985B1 (ko) 2024-05-29
JP2021113240A (ja) 2021-08-05
KR20240110000A (ko) 2024-07-12
SG10201913567QA (en) 2020-02-27
AU2016286108A1 (en) 2018-02-15
CN114853903A (zh) 2022-08-05
JP2018521999A (ja) 2018-08-09
KR20180016618A (ko) 2018-02-14
US11939367B2 (en) 2024-03-26
BR112017028316A2 (en) 2018-09-04
JP7559013B2 (ja) 2024-10-01
JP2022141840A (ja) 2022-09-29
EP3317297A1 (en) 2018-05-09
EP3317297A4 (en) 2019-03-20
AU2021203768A1 (en) 2021-07-08
US10961297B2 (en) 2021-03-30
JP7116285B2 (ja) 2022-08-10
US20240247047A1 (en) 2024-07-25
US20180170999A1 (en) 2018-06-21
CN108026159B9 (zh) 2022-07-05
WO2017004213A1 (en) 2017-01-05
IL256383A (en) 2018-02-28
IL256383B (en) 2022-11-01
IL297395B1 (en) 2023-09-01
AU2016286108A8 (en) 2018-02-22
MX2018000073A (es) 2018-06-27
US20220025017A1 (en) 2022-01-27
JP2024019529A (ja) 2024-02-09
AU2021203768B2 (en) 2023-01-19
IL297395B2 (en) 2024-01-01
CA2990885A1 (en) 2017-01-05
CN108026159B (zh) 2022-05-27
IL256383B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
AU2021203768B2 (en) BTLA fusion protein agonists and uses thereof
US20220380468A1 (en) Modulation of immune response using btla agonist antibodies
JP7240808B2 (ja) Ｐｓｇｌ－１モジュレーターおよびその使用
JP2023520587A (ja) 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト
EA043600B1 (ru) Слитые белки btla агонисты и их применение

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 6 , PAGE(S) 852 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, APPLICATION NO. 2016286108, UNDER INID (71) ADD CO-APPLICANT PFIZER INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Free format text: FORMER NAME(S): SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE; PFIZER INC.

Owner name: PFIZER INC.

Free format text: FORMER NAME(S): SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE; PFIZER INC.